Financial News

Crown Laboratories Completes Acquisition of Revance Therapeutics

The entities first announced the merger agreement – a deal valued at $924 million – in August 2024.

Author Image

By: Lianna Albrizio

Associate Editor

Crown Laboratories, Inc. has successfully closed its acquisition of biotechnology company Revance Therapeutics, Inc. The entities first announced the merger agreement – a deal valued at $924 million – in August 2024. Jeff Bedard, founder and CEO of Crown, previously said the combined entities would be afforded the opportunity to create a comprehensive portfolio of high-growth products for all stages of life, and that as a unit, would be committed to investing in education, training and pra...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters